Recommendation
- https://sleep.hms.harvard.edu/education-training/public-education/sleep-and-health-education-program/sleep-health-education-17Developing New Treatments | Sleep MedicineClarithromycin, flumazenil, and pentylenetetrazole can block GABA receptors. Although most patients treated with these drugs had other forms of excessive ...
- PubMed Central (PMC)https://pmc.ncbi.nlm.nih.gov/articles/PMC6982634/Recently Approved and Upcoming Treatments for Narcolepsy - PMCJan 17, 2020 ... JZP-258 is a novel low-sodium oxybate preparation in phase III development for treatment of cataplexy and EDS in patients with narcolepsy [44].
- https://www.mayoclinic.org/diseases-conditions/narcolepsy/diagnosis-treatment/drc-20375503Narcolepsy - Diagnosis and treatment - Mayo ClinicSolriamfetol (Sunosi) and pitolisant (Wakix) are newer stimulants used for narcolepsy. Pitolisant also may be helpful for cataplexy. Some people need treatment ...
- Neurology livehttps://www.neurologylive.com/view/ongoing-studies-and-new-treatments-for-narcolepsyOngoing Studies and New Treatments for NarcolepsyMay 17, 2024 ... Hypocretin agonists hold promise in addressing narcolepsy's underlying deficiency in the orexin system. Preliminary data on medications show ...
- PubMed Central (PMC)https://pmc.ncbi.nlm.nih.gov/articles/PMC6767718/Recent advances in treatment for narcolepsy - PMCSolriamfetol, a phenylalanine derivative with dopaminergic and noradrenergic activity will be soon a new therapeutic option to treat EDS in NT1 and NT2. Sodium ...
- PubMedhttps://pubmed.ncbi.nlm.nih.gov/31953791/Recently Approved and Upcoming Treatments for NarcolepsyPitolisant, an H3R antagonist, and solriamfetol, a dopamine and norepinephrine reuptake inhibitor, are the most recently approved treatments for EDS associated ...
- National Institute of Neurological Disorders and Strokehttps://www.ninds.nih.gov/health-information/disorders/narcolepsyNarcolepsy | National Institute of Neurological Disorders and StrokeJul 19, 2024 ... ... new therapies to control symptoms and may lead to a cure. Immune system. Abnormalities in the immune system may play an important role in the ...
- The New England Journal of Medicinehttps://www.nejm.org/doi/full/10.1056/NEJMoa2301940Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1 | New England ...Jul 26, 2023 ... We tested the efficacy and safety of TAK-994, a highly selective oral OX2R agonist that crosses the blood–brain barrier, for the treatment of ...
- News Centerhttps://med.stanford.edu/news/all-news/2021/09/narcolepsy-drug.htmlStanford researcher shows once-nightly narcolepsy drug is safe ...Sep 8, 2021 ... Sodium oxybate is approved by the Food and Drug Administration for the treatment of multiple narcolepsy symptoms, including excessive daytime ...
- The New England Journal of Medicinehttps://www.nejm.org/doi/full/10.1056/NEJMp2308308Awakened Hope for Narcolepsy: ITT Episode 17: New England ...Sep 13, 2023 ... In this podcast episode, a patient with narcolepsy describes her rough, long road to diagnosis and treatment, and a researcher elucidates ...
SK-Bloom, providing better quality news content.
All News
Others
- Terms of use Terms of use
- Contact Us Contact Us
- Privacy Policy Privacy Policy
2024 Copyright. All Rights Reserved.